LB1410

LB1410 is a bispecific antibody developed by L & L Bio, Ningbo, China. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM3). The sponsor states: Anti-PD-1/TIM3 bispecific antibody intended to block dual immune checkpoint pathways, given in combination with LB4330. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.